Trending Clinical Topic of the Week (July 7-13): Hyperhidrosis
Approval of a new product designed to help with a sometimes debilitating condition resulted in this week's top search term. The US Food and Drug Administration has approved topical glycopyrronium (Qbrexza) for the treatment of primary axillary hyperhidrosis. Hyperhidrosis is a condition characterized by excessive sweating that can impede normal daily activities, resulting in psychological, social, and physical impairment. Although hyperhidrosis may affect various regions of the body and may be idiopathic or secondary to other diseases, metabolic disorders, febrile illnesses, or medication use, the new treatment option is thus far indicated only for the primary axillary form of the condition. Qbrexza is a topical anticholinergic cloth that is applied to the underarms, resulting in a noticeable and sustained decrease in overall sweat production. The FDA has approved use in adults and children as young as 9 years. Prescribing information is available online. This week's trending clinical topic is undoubtedly associated with welcome news for patients and those caring for them.
For more information on hyperhidrosis, read here.
Medscape © 2018
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Ryan Syrek. Clinical Trends for July 2018 - Medscape - Jul 27, 2018.